6533b853fe1ef96bd12acb17
RESEARCH PRODUCT
Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.
Roberta NapolitanoMaria Teresa BochicchioGiulio GiordanoMariasanta NapolitanoAlessandro Lucchesisubject
Blood PlateletsQH301-705.5platelet functionMPNInflammationReviewDiseaseBioinformaticsFibrinogenModels BiologicalCatalysisPAR receptorLeukemia Myeloid Chronic Atypical BCR-ABL NegativeInorganic ChemistryTissue factorThrombinAntithromboticmedicineAnimalsHumansThrombophiliaPlateletPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyPAR receptorsbusiness.industryOrganic ChemistryThrombinGeneral MedicineComputer Science ApplicationsChemistryReceptors FibrinogenCoagulationthrombin generationBiological Assayfibrinogenmedicine.symptombusinessmedicine.drugdescription
Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and is self-maintained by Protease Activated Receptors (PARs). We chose to define this model as a “circulating wound”, as it indisputably links the coagulation, inflammation, and fibrotic progression of the disease, in analogy with what happens in some solid tumours. The platelet contribution to thrombin generation results in triggering a vicious circle supported by the PARs/TGF-beta axis. PAR antagonists could therefore be a good option for target therapy, both to contain the risk of vascular events and to slow the progression of the disease towards end-stage forms. Both the new and old strategies, however, will require tools capable of measuring procoagulant or prohaemorrhagic states in a more extensive and dynamic way to favour a less empirical management of MPNs and their potential clinical complications.
year | journal | country | edition | language |
---|---|---|---|---|
2021-10-20 | International journal of molecular sciences |